LGD-2226

LGD-2226 is a non-steroidal, non-aromatizable selective androgen receptor modulator (SARM), a class of compounds designed to activate the androgen receptor in a tissue-selective manner so as to deliver the anabolic benefits of androgens in muscle and bone while minimizing unwanted activity in tissues such as the prostate ^[1][2][3]. It was developed by Ligand Pharmaceuticals and reported in the mid-2000s as one of the early orally active SARMs ^[1].

In the foundational study, LGD-2226 bound the androgen receptor with high selectivity and showed full anabolic activity in cell-based models of bone and muscle; in rodents it produced anabolic effects on muscle and bone, enhanced bone strength above control levels, and remained efficacious in a model of male sexual behavior, all with markedly reduced impact on prostate growth compared with conventional androgens ^[1]. This separation of muscle-and-bone benefits from prostate stimulation is the hallmark property that motivates SARM development for indications such as osteoporosis, frailty, muscle wasting, and hypogonadism ^[2][3].

LGD-2226 itself did not advance to become an approved medicine and is best understood as a research compound and a proof of concept for the class; the broader SARM field has since produced later molecules that reached human testing, and a human trial of a related oral SARM confirmed increases in lean body mass with tissue-selective effects ^[4]. SARMs are not approved by regulators for these uses, are prohibited in sport by anti-doping authorities, and on the consumer market are frequently sold as grey-market research chemicals whose purity is not guaranteed ^[2][3].

LGD-2226 is an investigational selective androgen receptor modulator with essentially no human clinical data; like other SARMs it is expected to suppress the body's own testosterone production, worsen cholesterol by lowering HDL, and place strain on the liver. It is not an approved drug and is prohibited in sport, and the long-term consequences of use in humans are unknown.

LGD-2226 was discovered by the research group at Ligand Pharmaceuticals in San Diego and formally described in 2006 across two companion papers, a chemistry report in the Journal of Medicinal Chemistry by van Oeveren and colleagues and a pharmacology report in Endocrinology by Miner and colleagues. The molecule belongs to a series of 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones identified during an effort to create orally available, non-steroidal androgens.

Its stated purpose was to capture the bone- and muscle-building benefits of testosterone while sharply reducing the prostate-stimulating and other side effects that limit conventional androgen therapy. In rodent studies it proved fully active on muscle and bone, enhanced bone mechanical strength above baseline, and preserved male sexual behavior, all while producing much less prostate growth than classical androgens. As one of the earliest well-documented selective androgen receptor modulators, LGD-2226 helped establish the proof of concept that tissue selectivity through the androgen receptor was achievable, laying groundwork for the broader SARM field.

LGD-2226 holds an honored place in pharmacology as a foundational example of the SARM idea made real, cited repeatedly in reviews as evidence that a single molecule can act as a strong anabolic signal in muscle and bone yet remain relatively quiet in the prostate. Researchers were struck that it improved not only muscle and bone mass but also bone strength and sexual function in animals, and that these benefits arose without conversion to estrogen.

Because it is orally active, it pointed toward the convenience that later SARMs would pursue in place of injectable steroids. It is important to be candid that LGD-2226 remained an investigational compound and was never advanced into the large human trials needed to confirm efficacy or long-term safety, so its human profile is undocumented. Its lasting value is scientific and historical, as a clean early demonstration of androgen-receptor tissue selectivity that shaped an entire class.